⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of OncoNex-Remunity Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
OncoNex-Remunity Therapeutics
↗Houston, USA / Paris, France
OncoNex-Remunity Therapeutics is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company specializes in immune-stimulating antibody-drug conjugates (ADCs) designed to reactivate the anti-tumor immune response and overcome resistance to current cancer treatments.
Founded in 2024, the company operates internationally with bases in Houston, Texas, and Paris, France, and has recently established an Asia-Pacific headquarters in Hong Kong. It is supported by NxR Biotechnologies GmbH and is actively advancing a pipeline of legacy big pharma Phase I/II assets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:NxR Biotechnologies GmbH, HSITP (Ignite@HSITP program)
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Antibody-drug conjugates (ADC), Immunotherapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:NxR Biotechnologies GmbH (Support/Project), Texas Medical Center (TMC) Innovation (Accelerator cohort)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Alain Vertès - Co-founder and CEO
LINKS
Website:remunitytx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with OncoNex-Remunity Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.